High-resolution characterization of the pancreatic adenocarcinoma genome

被引:207
作者
Aguirre, AJ
Brennan, C
Bailey, G
Sinha, R
Feng, B
Leo, C
Zhang, YY
Zhang, J
Gans, JD
Bardeesy, N
Cauwels, C
Cordon-Cardo, C
Redston, MS
DePinho, RA
Chin, L [1 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[4] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
array comparative genomic hybridization expression profile;
D O I
10.1073/pnas.0402932101
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The pancreatic adenocarcinoma genome harbors multiple amplifications and deletions, pointing to the existence of numerous oncogenes and tumor suppressor genes driving the genesis and progression of this lethal cancer. Here, array comparative genomic hybridization on a cDNA microarray platform and informatics tools have been used to define the copy number alterations in a panel of 24 pancreatic adenocarcinoma cell lines and 13 primary tumor specimens. This high-resolution genomic analysis has identified all known regional gains and losses as well as many previously uncharacterized highly recurrent copy number alterations. A systematic prioritization scheme has selected 64 focal minimal common regions (MCRs) of recurrent copy number change. These MCRs possess a median size of 2.7 megabases (Mb), with 21 (33%) MCRs spanning 1 Mb or less (median of 0.33 Mb) and possessing an average of 15 annotated genes. Furthermore, complementary expression profile analysis of a significant fraction of the genes residing within these 64 prioritized MCRs has enabled the identification of a subset of candidates with statistically significant association between gene dosage and mRNA expression. Thus, the integration of DNA and RNA profiles provides a highly productive entry point for the discovery of genes involved in the pathogenesis of pancreatic adenocarcinoma.
引用
收藏
页码:9067 / 9072
页数:6
相关论文
共 41 条
  • [1] Abe T, 1999, GENE CHROMOSOME CANC, V25, P60, DOI 10.1002/(SICI)1098-2264(199905)25:1<60::AID-GCC9>3.0.CO
  • [2] 2-Y
  • [3] RTCGD: retroviral tagged cancer gene database
    Akagi, K
    Suzuki, T
    Stephens, RM
    Jenkins, NA
    Copeland, NG
    [J]. NUCLEIC ACIDS RESEARCH, 2004, 32 : D523 - D527
  • [4] Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene
    Albertson, DG
    Ylstra, B
    Segraves, R
    Collins, C
    Dairkee, SH
    Kowbel, D
    Kuo, WL
    Gray, JW
    Pinkel, D
    [J]. NATURE GENETICS, 2000, 25 (02) : 144 - 146
  • [5] DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma
    Armengol, G
    Knuutila, S
    Lluís, F
    Capellà, G
    Miró, R
    Caballín, MR
    [J]. CANCER GENETICS AND CYTOGENETICS, 2000, 116 (02) : 133 - 141
  • [6] Pancreatic cancer biology and genetics
    Bardeesy, N
    DePinho, RA
    [J]. NATURE REVIEWS CANCER, 2002, 2 (12) : 897 - 909
  • [7] KARYOTYPIC ABNORMALITIES IN TUMORS OF THE PANCREAS
    BARDI, G
    JOHANSSON, B
    PANDIS, N
    MANDAHL, N
    BAKJENSEN, E
    ANDRENSANDBERG, A
    MITELMAN, F
    HEIM, S
    [J]. BRITISH JOURNAL OF CANCER, 1993, 67 (05) : 1106 - 1112
  • [8] FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA
    CALDAS, C
    HAHN, SA
    DACOSTA, LT
    REDSTON, MS
    SCHUTTE, M
    SEYMOUR, AB
    WEINSTEIN, CL
    HRUBAN, RH
    YEO, CJ
    KERN, SE
    [J]. NATURE GENETICS, 1994, 8 (01) : 27 - 32
  • [9] Amplification of DNA sequences from chromosome 19q13.1 in human pancreatic cell lines
    Curtis, LJ
    Li, Y
    Gerbault-Seureau, M
    Kuick, R
    Dutrillaux, AM
    Goubin, G
    Fawcett, J
    Cram, S
    Dutrillaux, B
    Hanash, S
    Muleris, M
    [J]. GENOMICS, 1998, 53 (01) : 42 - 55
  • [10] Fukushige S, 1997, GENE CHROMOSOME CANC, V19, P161, DOI 10.1002/(SICI)1098-2264(199707)19:3<161::AID-GCC5>3.0.CO